Movement Disorders

In a recent multisite analysis of 361 patients with REM sleep behavior disorder, 84% had neurological abnormalities in at least one domain observed.

The associate professor in the department of neurology at the University of Rochester provided insight on her presentation on psychosis in Parkinson disease and related disorders given at the 2023 ANA Annual Meeting.

Approved in 2016, the newly updated label changes add more clarity to the use of pimavanserin, noting that patients with Parkinson disease with dementia may be eligible for treatment.

The movement disorder specialist at Cambridge University Hospitals NHS Foundation Trust talked about a patient with treatment-resistant Parkinson disease who experienced significant improvement in motor symptoms after using a vibrational therapy. [WATCH TIME: 8 minutes]

Marcio Souza, president and chief executive officer at Praxis Precision Medicines provided follow-up thoughts on recently announced positive findings assessing ulixacaltamide in patients with essential tremor.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer and dementia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 15, 2023.

Stuart H. Isaacson, MD, FAAN, speaks to the current understanding of genetics and other factors in the individualization of care for patients with Parkinson disease.

An expert comments on the impact of factors such as disease course, antibody status, and patient adherence on the management of gMG.

A physician expert discusses the socioeconomic burden of gMG on both the patient and the caregiver.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke.

Neurology News Network for the week ending September 9, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 8, 2023.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James Beck, PhD. [LISTEN TIME: 15 minutes]

The president of the ANA and the chair of the annual meeting programming committee provided commentary on the advances in neurology and the shift in how clinicians approach and treat diseases once thought to be fatal. [WATCH TIME: 6 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of August 2023, compiled all into one place by the NeurologyLive® team.

The president of the ANA and the chair of the annual meeting programming committee gave an overview on the various topics and courses the clinical community should home in on at the upcoming annual meeting. [WATCH TIME: 6 minutes]

An expert panel discusses diagnosis and treatment of patients with Parkinson disease, exploring the challenges in managing dyskinesia, finding a balance between OFF episodes and ON time, and current and emerging treatment options.

Nicolaas Bohnen, MD, PhD, professor of radiology and neurology at the University of Michigan, discussed the main takeaways from his keynote lecture on posture and gait in Parkinson disease presented at the 2023 MDS Congress.

The president of the ANA and the chair of the annual meeting programming committee provided perspective on the upcoming ANA Annual Meeting and what clinicians may get out of the meeting. [WATCH TIME: 7 minutes]

More than a 40% improvement in ON time without troublesome dyskinesia occurred as patients had their treatment titrated.

On average, clinician-rated TD severity, measured by AIMS, and patient-reported assessment of the physical, social and emotional impact of TD, measured by TDIS, decreased with one-capsule, once-daily valbenazine over 48 weeks.

Here's some of what is coming soon to NeurologyLive® this week.